[Pe-058] English Poster Session 058

[Pe-058-4] Randomized controlled study of the efficacy of natalizumab 6-week vs continued 4-week dosing for MS

^○John Foley¹, Defer Gilles², Zhovtis Ryerson Lana³, Cohen Jeffrey A.⁴, Arnold Doug L.⁵, Butzkueven Helmut⁶, Cutter Gary⁷, Giovannoni Gavin⁸, Killestein Joep⁹, Wiendl Heinz¹⁰, Smirnakis Karen¹¹, Xiao Shan¹¹, Kong George¹¹, Kuhelj Robert¹¹, Campbell Nolan¹¹ (1.Rocky Mountain MS Clinic, USA, 2.Institute of Translational Neurology, University of Munster, 3.Biogen, 4.Centre Hospitalier Universitaire de Caen, 5.NYU Langone Health, New York University, 6.Cleveland Clinic, 7.Montreal Neurological Institute, McGill University, and NeuroRx Research, 8.Central Clinical School, Monash University, 9.University of Alabama School of Public Health, 10.Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 11.MS Centre Amsterdam, VU University Medical Centres)